Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
ViroMissile, Inc.
Children's Oncology Group
Essen Biotech
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
DualityBio Inc.
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
Incyte Corporation
University of Pittsburgh
Sotio Biotech Inc.
Mayo Clinic
GV20 Therapeutics
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
West China Hospital
DualityBio Inc.
M.D. Anderson Cancer Center
GlaxoSmithKline
University of Pittsburgh
Eisai Inc.
HiFiBiO Therapeutics
7 Hills Pharma, LLC
Pfizer
Incyte Corporation
Cancer Research UK
University of Virginia
Incyte Corporation
UNICANCER
Incyte Corporation
Incyte Corporation
University of Pittsburgh
Sotio Biotech Inc.
Children's National Research Institute
GI Innovation, Inc.
Molecular Templates, Inc.
Salubris Biotherapeutics Inc
National Cancer Institute (NCI)
Xencor, Inc.
Pliant Therapeutics, Inc.
Exelixis
BioEclipse Therapeutics